论文部分内容阅读
目的应用99Tc-MDP治疗乳腺癌芳香化酶抑制剂(AI)辅助内分泌治疗后骨关节、肌肉痛,探讨其临床价值。方法收集2003年1月至2007年3月间乳腺癌AI辅助内分泌治疗后骨关节、肌肉痛患者74例,随机分为二组:99Tc-MDP加服钙尔奇D组(A组)34例,单服钙尔奇D组(B组)40例。比较两组对疼痛的缓解效果。结果骨关节、肌肉痛症状缓解情况:A组总有效率为94.1%,B组为52.5%,两组差异有统计学意义(P<0.001)。结论99Tc-MDP使用简便、安全、疗效满意、不良反应少,值得临床推广应用于缓解绝经后乳腺癌AI辅助内分泌治疗后的骨关节、肌肉痛。
Objective To investigate the clinical value of 99Tc-MDP in the treatment of bone-joint and muscle pain after adjuvant endocrine therapy with breast cancer Aromatase Inhibitor (AI). Methods 74 patients with osteoarthritis and muscular dystrophy after AI-assisted endocrine therapy of breast cancer from January 2003 to March 2007 were randomly divided into two groups: 99Tc-MDP group and 34 cases in group A , Single serving of calcium Erqi D group (B group) 40 cases. The pain relief was compared between the two groups. Results The relief of the symptoms of osteoarthritis and muscular pain was 94.1% in group A and 52.5% in group B, with significant difference between the two groups (P <0.001). Conclusion 99Tc-MDP is simple and safe to use, with satisfactory curative effect and few side effects. It is worthy of clinical application to relieve bone-joint and muscle pain after AI-assisted endocrine therapy in postmenopausal women with breast cancer.